Our aim was to determine the feasibility of 18F-florbetaben PET in diagnosing cardiac
amyloidosis. Methods: 18F-florbetaben PET was performed on 14 patients: 5 amyloid light …

Purpose Cardiac amyloidosis, a restrictive heart disease with high mortality and morbidity, is
underdiagnosed due to limited targeted diagnostic imaging. The primary aim of this study …

Objective Cardiac amyloidosis is a rare disease characterized by amyloid heart deposits
and is usually a part of systemic amyloidosis, in relation to systemic light chain (AL) and …

Introduction Cardiac amyloidosis is a rare condition characterized by the deposition of well-
structured protein fibrils, proteoglycans, and serum proteins as amyloid. Recent work has …

Purpose 18 F-Florbetapir has been reported to show cardiac uptake in patients with
systemic light-chain amyloidosis (AL). This study systematically assessed uptake of 18 F …

Background Non-invasive imaging to diagnose and quantify amyloid load, progression, and
response to treatment are central for the care of patients with cardiac amyloidosis. 18 …

Background Conventional nuclear imaging with bone-seeking radiopharmaceuticals has
been shown to be a sensitive test for the detection of transthyretin cardiac amyloidosis …

Purpose Cardiac amyloidosis (CA) is a rare cause of heart failure with frequently delayed
diagnosis, because specific early signs or symptoms are missing. Recently, direct amyloid …

Cardiac amyloidosis is a differential diagnosis in heart failure and is associated with high
mortality. There is currently no noninvasive imaging test available for specific diagnosis. N …

Background—18F-florbetapir is a promising imaging biomarker for cardiac light chain
amyloidosis (AL) and transthyretin amyloidosis (ATTR). Our aim, using human autopsy …